+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Rituximab"

From
From
Lupus Nephritis - Pipeline Insight, 2025 - Product Thumbnail Image

Lupus Nephritis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
From
From
Dermatomyositis - Pipeline Insight, 2025 - Product Thumbnail Image

Dermatomyositis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
IgG4-Related Disease - Pipeline Insight, 2025 - Product Thumbnail Image

IgG4-Related Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
From
From
Multifocal Motor Neuropathy Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Multifocal Motor Neuropathy Epidemiology Forecast 2025-2034

  • Report
  • June 2025
  • 150 Pages
  • Global
From
Lupus Nephritis Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Lupus Nephritis Epidemiology Forecast 2025-2034

  • Report
  • June 2025
  • 150 Pages
  • Global
From
From
From
Psoriatic Arthritis Pipeline Analysis Report 2025 - Product Thumbnail Image

Psoriatic Arthritis Pipeline Analysis Report 2025

  • Report
  • June 2025
  • 200 Pages
  • Global
From
From
Anti-cd20 Monoclonal Antibodies (mabs) Market 2025-2029 - Product Thumbnail Image

Anti-cd20 Monoclonal Antibodies (mabs) Market 2025-2029

  • Report
  • March 2025
  • 255 Pages
  • Global
From
Myasthenia Gravis: Opportunity Assessment and Forecast - Product Thumbnail Image

Myasthenia Gravis: Opportunity Assessment and Forecast

  • Report
  • June 2025
  • 85 Pages
  • Global
From
Loading Indicator

Rituximab is a monoclonal antibody used to treat a variety of immune disorders, including rheumatoid arthritis, systemic lupus erythematosus, and non-Hodgkin's lymphoma. It works by targeting and destroying B-cells, which are a type of white blood cell involved in the body's immune response. Rituximab is administered intravenously and is often used in combination with other drugs. Rituximab is a relatively new drug, having been approved by the US Food and Drug Administration in 1997. Since then, it has become a popular treatment for immune disorders, due to its effectiveness and relatively low side effects. It is also used off-label to treat a variety of other conditions, such as multiple sclerosis and vasculitis. The market for rituximab is highly competitive, with several major pharmaceutical companies producing the drug. These include Roche, Merck, Pfizer, and Biogen. Additionally, there are several generic versions of the drug available, produced by companies such as Sandoz and Teva Pharmaceuticals. Show Less Read more